Isomorphic Labs has made significant strides in drug design with the introduction of their Drug Design Engine (IsoDDE). This system drastically improves predictive accuracy for biomolecular structures and interactions, more than doubling the accuracy of AlphaFold 3 on complex protein-ligand predictions. IsoDDE can predict small molecule binding affinities faster and more accurately than traditional physics-based methods, making it a game changer for drug discovery. One standout feature of IsoDDE is its ability to identify novel binding pockets on proteins using just the amino acid sequence as input. This capability allows researchers to explore previously unknown regions of biomolecular space, which are often key to addressing major challenges in drug development. For instance, IsoDDE successfully predicted both known and newly discovered binding sites on the cereblon protein, which plays a crucial role in protein degradation. This was achieved without prior knowledge of the ligands involved, showcasing IsoDDE's power in identifying potential new therapeutic targets. In terms of modeling antibody-antigen interactions, IsoDDE outperforms AlphaFold 3 by 2.3 times and Boltz-2 by nearly 20 times on certain tests. This enhanced accuracy is particularly important for antibody design, especially in predicting the complex CDR-H3 loop. IsoDDE also excels in predicting binding affinities, surpassing all deep-learning methods and even matching the performance of physics-based approaches, which typically rely on experimental data. By delivering accurate predictions quickly, IsoDDE helps researchers efficiently evaluate and optimize candidate molecules during drug design processes.